Rate of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Use and the Number of COVID-19–Confirmed Cases and Deaths

The novel coronavirus SARS-CoV-2 uses the angiotensin-converting enzyme 2 receptor as an entry point to the cell. Cardiovascular disease (CVD) is a risk factor for COVID-19 with poor outcomes. We tested the hypothesis that the rate of angiotensin-converting enzyme inhibitor (ACEI) and angiotensin re...

Descripción completa

Detalles Bibliográficos
Autores principales: Tereshchenko, Larisa G., Johnson, Kyle, Khayyat-Kholghi, Maedeh, Johnson, Blake
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665655/
https://www.ncbi.nlm.nih.gov/pubmed/34906367
http://dx.doi.org/10.1016/j.amjcard.2021.10.050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665655/
https://www.ncbi.nlm.nih.gov/pubmed/34906367
http://dx.doi.org/10.1016/j.amjcard.2021.10.050

Ejemplares similares